These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 9838913)

  • 1. [Comparison of crossing-over between 30-minute drip infusion vs 30-second injection of granisetron for nausea and vomitting with cisplatin].
    Satoh Y; Oshima T; Takahashi N; Ogawa H; Shiroto H; Akasaka Y; Nakanishi Y; Uchino J; Koshino I; Une Y; Todo S
    Gan To Kagaku Ryoho; 1998 Nov; 25(13):2101-8. PubMed ID: 9838913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
    Fujii M; Ohno Y; Tokumaru Y; Imanishi Y; Kanke M; Kanzaki J
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1095-101. PubMed ID: 9239162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical evaluation of granisetron injection against nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Tanaka K; Hataya I; Tokunaga A; Takeuchi Y; Hanaoka J; Yanase T; Takahashi T; Maruhashi T
    Gan To Kagaku Ryoho; 1994 Aug; 21(10):1641-6. PubMed ID: 8060140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison of antiemetic efficacy of granisetron as premedication versus combination therapy of granisetron].
    Ikeda H; Koshiba R
    Gan To Kagaku Ryoho; 1998 Oct; 25(12):1947-53. PubMed ID: 9797818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
    Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of granisetron in preventing emesis due to anti-cancer drug (CDDP) administration pulmo-mediastinal malignancies--comparison of simultaneous infusion with the conventional method of administration].
    Nakahara K; Minami M; Yasumitsu T; Ikeda M; Ohta M; Nakamura K; Akashi A; Kido T
    Gan To Kagaku Ryoho; 1998 Mar; 25(4):571-6. PubMed ID: 9530364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy and safety of two methods of administration of granisetron injection for nausea and vomiting induced by chemotherapy for tumors in hematopoietic organs--a randomized crossover comparison between intravenous drip infusion and intravenous bolus injection].
    Tsudo M; Moriguchi T
    Gan To Kagaku Ryoho; 1998 Sep; 25(11):1747-53. PubMed ID: 9757201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of 2 mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
    Takada M; Furuse K; Fukuoka M; Kawahara M; Negoro S; Kusunoki Y; Ogawara M; Furue H
    Gan To Kagaku Ryoho; 1997 Jun; 24(8):987-94. PubMed ID: 9212809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
    Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
    Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of 2-mg granisetron tablet for nausea and vomiting induced by anticancer drugs including cisplatin].
    Yoshiya N; Kodama S; Aoki Y; Takahashi T; Honma S; Endo M; Tokunaga A; Takeuchi Y; Hanaoka J; Maruhashi T; Oshima T; Tanaka K; Furue H
    Gan To Kagaku Ryoho; 1997 Jul; 24(9):1141-7. PubMed ID: 9239168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
    Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
    Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of ondansentron treatment for acute emesis with different dosing schedules 8 vs 32 mg. A randomized study.
    Tsavaris N; Kosmas CH; Vadiaka M; Kontos A; Katsorida M; Dimitrakopoulos A; Zerai A; Koufos CH
    J Exp Clin Cancer Res; 2001 Mar; 20(1):29-34. PubMed ID: 11370826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials.
    Warr DG; Grunberg SM; Gralla RJ; Hesketh PJ; Roila F; Wit Rd; Carides AD; Taylor A; Evans JK; Horgan KJ
    Eur J Cancer; 2005 Jun; 41(9):1278-85. PubMed ID: 15939263
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869.
    Van Belle S; Lichinitser MR; Navari RM; Garin AM; Decramer ML; Riviere A; Thant M; Brestan E; Bui B; Eldridge K; De Smet M; Michiels N; Reinhardt RR; Carides AD; Evans JK; Gertz BJ
    Cancer; 2002 Jun; 94(11):3032-41. PubMed ID: 12115394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of droperidol in the prevention of cisplatin-induced delayed emesis: a double-blind, randomised parallel study.
    Minegishi Y; Ohmatsu H; Miyamoto T; Niho S; Goto K; Kubota K; Kakinuma R; Kudoh S; Nishiwaki Y
    Eur J Cancer; 2004 May; 40(8):1188-92. PubMed ID: 15110882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of concurrent use of ondansetron hydrochloride and dexamethasone against nausea and vomiting in lung cancer patients receiving cisplatin].
    Tanimura S; Banba J; Tomoyasu H; Masaki M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2275-81. PubMed ID: 9881085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of ramosetron plus dexamethasone in the prevention of cisplatin-induced nausea and vomiting.
    Voravud N; Sriuranpong V
    J Med Assoc Thai; 2005 Dec; 88(12):1790-6. PubMed ID: 16518975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the efficacy and safety of oral granisetron plus dexamethasone with intravenous ondansetron plus dexamethasone to control nausea and vomiting induced by moderate/severe emetogenic chemotherapy.
    Chiou TJ; Tzeng WF; Wang WS; Yen CC; Fan FS; Liu JH; Chen PM
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Oct; 63(10):729-36. PubMed ID: 11076429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
    J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.